Iterum Therapeutics PLC

Contributing Author

Recent Articles by Iterum Therapeutics PLC

Nov-07	Iterum Therapeutics to Report Third Quarter 2025 Financial Results on Friday, November 14, 2025 ITRM GlobeNewswire
Oct-14	Iterum Therapeutics to Present Data at IDWeek 2025 ITRM GlobeNewswire
Sep-19	Iterum Therapeutics Provides Business Update ITRM GlobeNewswire
Aug-20	Iterum Therapeutics launches ORLYNVAH, the first and only oral penem antibiotic in the U.S. ITRM GlobeNewswire
Aug-05	Iterum Therapeutics Reports Second Quarter 2025 Financial Results ITRM GlobeNewswire
Jul-29	Iterum Therapeutics to Report Second Quarter 2025 Financial Results on August 5, 2025 ITRM GlobeNewswire
Jul-02	Iterum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) ITRM GlobeNewswire
Jun-30	Iterum Names Christine Coyne as Chief Commercial Officer to Lead ORLYNVAH Launch and Commercial Growth ITRM GlobeNewswire
Jun-25	Iterum Therapeutics Announces Publication of REASSURE Trial in NEJM Evidence ITRM GlobeNewswire
Jun-11	Iterum Therapeutics Announces Partnership for Commercialization Services ITRM GlobeNewswire
May-19	Iterum Therapeutics Announces Extension of Term of Promissory Note ITRM GlobeNewswire
May-13	Iterum Therapeutics Reports First Quarter 2025 Financial Results ITRM GlobeNewswire
May-06	Iterum Therapeutics to Report First Quarter 2025 Financial Results on May 13, 2025 ITRM GlobeNewswire